📊 TNXP Key Takeaways
Is Tonix Pharmaceuticals Holding Corp. (TNXP) a Good Investment?
Tonix Pharmaceuticals is a pre-commercial stage biotech company with minimal revenue ($6.9M) and massive operating losses ($-41.5M), generating negative free cash flow of $-44M annually. Despite holding $185.5M in cash and minimal debt, providing approximately 4+ years of financial runway, the company exhibits no clear path to profitability and operates with expenses 6x revenue, indicating significant execution risk inherent to early-stage pharmaceutical development.
Why Buy Tonix Pharmaceuticals Holding Corp. Stock? TNXP Key Strengths
- Strong balance sheet with $185.5M cash reserves and minimal debt (0.04x Debt/Equity) providing extended operational runway
- Excellent liquidity position (6.99x current ratio) ensuring near-term financial stability and flexibility
- Revenue growth of 29.8% YoY and 91.7% improvement in diluted EPS losses indicating operational traction from baseline
- 7 Form 4 insider filings in 90 days suggesting management activity and engagement
TNXP Stock Risks: Tonix Pharmaceuticals Holding Corp. Investment Risks
- Massive operating losses ($-41.5M) on minimal revenue indicating development-stage company with unproven business model
- Negative free cash flow ($-44M annually) unsustainable without external funding despite cash reserves
- Pharmaceutical sector dependency on FDA approvals and clinical trial success with inherent regulatory and execution risk
- Revenue base of $6.9M insufficient to offset operating expenses, suggesting pre-commercial status with high uncertainty
- Operating expenses 6x revenue indicates company not approaching profitability within visible timeline
Key Metrics to Watch
- Drug pipeline advancement and FDA approval status/timeline for lead candidates
- Monthly cash burn rate and projected runway depletion date
- Revenue growth rate sustainability and product commercialization milestones
- Operating expense ratio trends and path to positive operating cash flow
Tonix Pharmaceuticals Holding Corp. (TNXP) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 6.99x current ratio provides a solid financial cushion.
TNXP Profit Margin, ROE & Profitability Analysis
TNXP vs Healthcare Sector: How Tonix Pharmaceuticals Holding Corp. Compares
How Tonix Pharmaceuticals Holding Corp. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Tonix Pharmaceuticals Holding Corp. Stock Overvalued? TNXP Valuation Analysis 2026
Based on fundamental analysis, Tonix Pharmaceuticals Holding Corp. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Tonix Pharmaceuticals Holding Corp. Balance Sheet: TNXP Debt, Cash & Liquidity
TNXP Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Tonix Pharmaceuticals Holding Corp.'s revenue has grown significantly by 69% over the 5-year period, indicating strong business expansion. The most recent EPS of $-176.60 indicates the company is currently unprofitable.
TNXP Revenue Growth, EPS Growth & YoY Performance
TNXP Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $2.4M | -$16.8M | $-2.84 |
| Q3 2025 | $2.8M | -$14.2M | $-3.59 |
| Q2 2025 | $2.0M | -$14.9M | $-3.86 |
| Q1 2025 | $2.4M | -$14.9M | $-2.84 |
| Q3 2024 | $2.8M | -$14.2M | $-0.23 |
| Q2 2024 | $2.2M | -$14.9M | $-19.28 |
| Q1 2024 | $2.5M | -$14.9M | $-0.18 |
| Q3 2023 | $4.0M | -$23.1M | $-1.83 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Tonix Pharmaceuticals Holding Corp. Dividends, Buybacks & Capital Allocation
TNXP SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Tonix Pharmaceuticals Holding Corp. (CIK: 0001430306)
📋 Recent SEC Filings
❓ Frequently Asked Questions about TNXP
What is the AI rating for TNXP?
Tonix Pharmaceuticals Holding Corp. (TNXP) has an AI rating of SELL with 72% confidence, based on fundamental analysis of SEC EDGAR filings.
What are TNXP's key strengths?
Claude: Strong balance sheet with $185.5M cash reserves and minimal debt (0.04x Debt/Equity) providing extended operational runway. Excellent liquidity position (6.99x current ratio) ensuring near-term financial stability and flexibility.
What are the risks of investing in TNXP?
Claude: Massive operating losses ($-41.5M) on minimal revenue indicating development-stage company with unproven business model. Negative free cash flow ($-44M annually) unsustainable without external funding despite cash reserves.
What is TNXP's revenue and growth?
Tonix Pharmaceuticals Holding Corp. reported revenue of $6.9M.
Does TNXP pay dividends?
Tonix Pharmaceuticals Holding Corp. does not currently pay dividends.
Where can I find TNXP SEC filings?
Official SEC filings for Tonix Pharmaceuticals Holding Corp. (CIK: 0001430306) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is TNXP's EPS?
Tonix Pharmaceuticals Holding Corp. has a diluted EPS of $-2.93.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is TNXP a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Tonix Pharmaceuticals Holding Corp. has a SELL rating with 72% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is TNXP stock overvalued or undervalued?
Valuation metrics for TNXP: ROE of -17.7% (sector avg: 15%), net margin of -584.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy TNXP stock in 2026?
Our dual AI analysis gives Tonix Pharmaceuticals Holding Corp. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is TNXP's free cash flow?
Tonix Pharmaceuticals Holding Corp.'s operating cash flow is $-42.3M, with capital expenditures of $1.7M. FCF margin is -639.9%.
How does TNXP compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -584.4% (avg: 12%), ROE -17.7% (avg: 15%), current ratio 6.99 (avg: 2).